Masimo Co. (NASDAQ:MASI) Expected to Post Quarterly Sales of $293.58 Million

Equities analysts forecast that Masimo Co. (NASDAQ:MASIGet Rating) will post $293.58 million in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Masimo’s earnings, with estimates ranging from $285.40 million to $301.76 million. Masimo reported sales of $299.04 million in the same quarter last year, which indicates a negative year-over-year growth rate of 1.8%. The firm is expected to issue its next quarterly earnings report after the market closes on Monday, January 1st.

According to Zacks, analysts expect that Masimo will report full year sales of $1.35 billion for the current year. For the next fiscal year, analysts expect that the company will post sales of $1.49 billion, with estimates ranging from $1.47 billion to $1.52 billion. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that follow Masimo.

Masimo (NASDAQ:MASIGet Rating) last released its earnings results on Tuesday, February 15th. The medical equipment provider reported $1.21 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.10 by $0.11. The business had revenue of $327.58 million for the quarter, compared to analyst estimates of $320.75 million. Masimo had a return on equity of 16.06% and a net margin of 18.53%. The company’s revenue for the quarter was up 11.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.98 earnings per share.

A number of research analysts have recently issued reports on MASI shares. UBS Group dropped their target price on Masimo from $325.00 to $295.00 and set a “buy” rating on the stock in a report on Wednesday, February 16th. StockNews.com started coverage on Masimo in a report on Thursday, March 31st. They issued a “buy” rating on the stock. Needham & Company LLC raised Masimo from a “hold” rating to a “buy” rating and set a $205.00 target price on the stock in a report on Friday, February 18th. Wolfe Research initiated coverage on Masimo in a report on Tuesday, April 5th. They set a “market perform” rating and a $160.00 price objective on the stock. Finally, Stifel Nicolaus dropped their price objective on Masimo from $250.00 to $175.00 and set a “buy” rating on the stock in a report on Thursday, March 31st. Three analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $229.00.

In other Masimo news, Director Adam Mikkelson sold 600 shares of the business’s stock in a transaction on Monday, January 24th. The stock was sold at an average price of $214.80, for a total transaction of $128,880.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 9.10% of the stock is currently owned by insiders.

Several large investors have recently modified their holdings of MASI. Janney Montgomery Scott LLC lifted its position in shares of Masimo by 2.1% in the third quarter. Janney Montgomery Scott LLC now owns 5,837 shares of the medical equipment provider’s stock valued at $1,580,000 after acquiring an additional 120 shares in the last quarter. GWM Advisors LLC lifted its position in shares of Masimo by 4.6% in the third quarter. GWM Advisors LLC now owns 1,556 shares of the medical equipment provider’s stock valued at $421,000 after acquiring an additional 68 shares in the last quarter. Nordea Investment Management AB lifted its position in shares of Masimo by 100.0% in the third quarter. Nordea Investment Management AB now owns 4,958 shares of the medical equipment provider’s stock valued at $1,350,000 after acquiring an additional 2,479 shares in the last quarter. AE Wealth Management LLC lifted its position in shares of Masimo by 10.9% in the third quarter. AE Wealth Management LLC now owns 1,694 shares of the medical equipment provider’s stock valued at $459,000 after acquiring an additional 166 shares in the last quarter. Finally, Asset Management One Co. Ltd. lifted its position in shares of Masimo by 59.9% in the third quarter. Asset Management One Co. Ltd. now owns 35,784 shares of the medical equipment provider’s stock valued at $9,685,000 after acquiring an additional 13,399 shares in the last quarter. Institutional investors and hedge funds own 82.82% of the company’s stock.

NASDAQ:MASI opened at $124.92 on Friday. The firm has a market cap of $6.93 billion, a P/E ratio of 31.39 and a beta of 0.89. The stock’s 50 day simple moving average is $148.96 and its 200-day simple moving average is $226.61. Masimo has a 12-month low of $124.65 and a 12-month high of $305.21.

Masimo Company Profile (Get Rating)

Masimo Corporation develops, manufactures, and markets noninvasive monitoring technologies and hospital automation solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.

Featured Articles

Get a free copy of the Zacks research report on Masimo (MASI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Masimo (NASDAQ:MASI)

Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.